Lifecore BiomedicalLFCR
LFCR
About: Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
Employees: 524
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
13% more funds holding
Funds holding: 76 [Q4 2024] → 86 (+10) [Q1 2025]
1.2% less ownership
Funds ownership: 67.39% [Q4 2024] → 66.19% (-1.2%) [Q1 2025]
6% less capital invested
Capital invested by funds: $203M [Q4 2024] → $190M (-$12.5M) [Q1 2025]
11% less call options, than puts
Call options by funds: $24K | Put options by funds: $27K
14% less funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 6 (-1) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for LFCR.
Financial journalist opinion
Based on 7 articles about LFCR published over the past 30 days
Neutral
Seeking Alpha
3 days ago
Stock Picks From Seeking Alpha's June 2025 New Analysts
June saw a record number of 48 new Seeking Alpha analysts, each bringing fresh stock ideas and unique backgrounds to the platform. Analysts provided ratings from Sell to Buy, with detailed justifications based on market trends, company fundamentals, and sector-specific challenges. Key investment theses include bullish views on Alphabet, TSM, AppLovin, and Rolls-Royce, a bearish call Samsara, and a neutral stance on SoundHound AI.
Positive
Seeking Alpha
3 weeks ago
Lifecore Biomedical: Inflecting Financials Over Next 3 Years
Lifecore Biomedical is emerging from a challenging restructuring and is now a pure play CDMO with new management, an improved balance sheet, expanded capacity, and a solid business plan. Industry dynamics and recent M&A suggest a decent chance of a near-term acquisition, potentially valuing LFCR at 2x its current price. LFCR's growth runway and customer stickiness support its premium valuation, but risks include easing capacity constraints and an uncertain exit multiple.
Neutral
Accesswire
3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Neutral
GlobeNewsWire
3 weeks ago
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer
CHASKA, Minn., June 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a new 10-year commercial manufacturing and supply agreement with a key existing customer.
Neutral
Accesswire
3 weeks ago
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Neutral
Accesswire
4 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Neutral
GlobeNewsWire
4 weeks ago
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale
Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach
Neutral
Accesswire
1 month ago
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Neutral
Accesswire
1 month ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Neutral
Accesswire
1 month ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Charts implemented using Lightweight Charts™